Emerging insights into the mechanistic link between α-synuclein and glucocerebrosidase in Parkinson's disease

Biochemical Society Transactions

Volumn 41, Issue 6, 2013, Pages 1509-1512

  McGlinchey, Ryan P ^a   Lee, Jennifer C ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

synuclein; Amyloid; Gaucher disease; Glucocerebrosidase; Lysosome; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; GLUCOSYLCERAMIDASE;

CONFERENCE PAPER; DISEASE COURSE; ENZYME ACTIVITY; ENZYME MECHANISM; GAUCHER DISEASE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HUMAN; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

ALPHA-SYNUCLEIN; ANIMALS; GLUCOSYLCERAMIDASE; HUMANS; PARKINSON DISEASE;

EID: 84887948427     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST20130158     Document Type: Conference Paper

References (43)

1. Butters, T.D. (2007) Gaucher disease. Curr. Opin. Chem. Biol. 11, 412-418
2. Hruska, K.S., LaMarca, M.E., Scott, C.R. and Sidransky, E. (2008) Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum. Mutat. 29, 567-583
3. Grabowski, G.A. (1997) Gaucher disease: gene frequencies and genotype/phenotype correlations. Genet. Test. 1, 5-12
4. Grabowski, G.A. (2008) Lysosomal storage disease 1: phenotype, diagnosis, and treatment of Gaucher's disease. Lancet 372, 1263-1271
5. Lee, V.M.Y. and Trojanowski, J.Q. (2006) Mechanisms of Parkinson's disease linked to pathological α-synuclein: new targets for drug discovery. Neuron 52, 33-38
6. Uversky, V.N. and Eliezer, D. (2009) Biophysics of Parkinson's disease: structure and aggregation of α-synuclein. Curr. Protein Pept. Sci. 10, 483-499
7. Dev, K.K., Hofele, K., Barbieri, S., Buchman, V.L. and van der Putten, H. (2003) Part II: α-synuclein and its molecular pathophysiological role in neurodegenerative disease. Neuropharmacology 45, 14-44
8. Polymeropoulos, M.H., Lavedan, C., Leroy, E., Ide, S.E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R. et al. (1997) Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047
9. Zarranz, J.J., Alegre, J., Gomez-Esteban, J.C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atares, B. et al. (2004) The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55, 164-173
10. Proukakis, C., Dudzik, C.G., Brier, T., MacKay, D.S., Cooper, J.M., Millhauser, G.L., Houlden, H. and Schapira, A.H. (2013) A novel α-synuclein missense mutation in Parkinson disease. Neurology 80, 1062-1064
11. Lesage, S., Anheim, M., Letournel, F., Bousset, L., Honore, A., Rozas, N., Pieri, L., Madiona, K., Durr, A., Melki, R. et al. (2013) G51D α-synuclein mutation causes a novel parkinsonian-pyramidal syndrome. Ann. Neurol. 73, 459-471
12. Kruger, R., Kuhn, W., Muller, T., Woitalla, D., Graeber, M., Kosel, S., Przuntek, H., Epplen, J.T., Schols, L. and Riess, O. (1998) Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat. Genet. 18, 106-108
13. Chartier-Harlin, M.C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M. et al. (2004) α-Synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364, 1167-1169
14. Singleton, A.B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R. et al. (2003) α-Synuclein locus triplication causes Parkinson's disease. Science 302, 841-841
15. Sidransky, E., Nalls, M.A., Aasly, J.O., Aharon-Peretz, J., Annesi, G., Barbosa, E.R., Bar-Shira, A., Berg, D., Bras, J., Brice, A. et al. (2009) Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N. Engl. J. Med. 361, 1651-1661
16. Sidransky, E. and Lopez, G. (2012) The link between the GBA gene and parkinsonism. Lancet Neurol. 11, 986-998
17. Yang, N.Y., Lee, Y.N., Lee, H.J., Kim, Y.S. and Lee, S.J. (2013) Glucocerebrosidase, a new player changing the old rules in Lewy body diseases. Biol. Chem. 394, 807-818
18. Mak, S.K., McCormack, A.L., Manning-Bog, A.B., Cuervo, A.M. and Di Monte, D.A. (2010) Lysosomal degradation of α-synuclein in vivo. J. Biol. Chem. 285, 13621-13629
19. Halperin, A., Elstein, D. and Zimran, A. (2006) Increased incidence of Parkinson disease among relatives of patients with Gaucher disease. Blood Cells Mol. Dis. 36, 426-428
20. Wong, K.D., Sidransky, E., Verma, A., Mixon, T.H., Sandberg, G.D., Wakefield, L.K., Morrison, A., Lwin, A., Colegial, C., Allman, J.M. and Schiffmann, R. (2004) Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol. Genet. Metab. 82, 192-207
21. Gegg, M.E., Burke, D., Heales, S.J.R., Cooper, J.M., Hardy, J., Wood, N.W. and Schapira, A.H.V. (2012) Glucocerebrosidase deficiency in substantia nigra of Parkinson disease brains. Ann. Neurol. 72, 455-463
22. Cullen, V., Sardi, P., Ng, J., Xu, Y.H., Sun, Y., Tomlinson, J.J., Kolodziej, P., Kahn, I., Saftig, P., Woulfe, J. et al. (2011) Acid β-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter α-synuclein processing. Ann. Neurol. 69, 940-953
23. Mazzulli, J.R., Xu, Y.H., Sun, Y., Knight, A.L., McLean, P.J., Caldwell, G.A., Sidransky, E., Grabowski, G.A. and Krainc, D. (2011) Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146, 37-52
24. Manning-Bog, A.B., Schule, B. and Langston, J.W. (2009) α-Synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism. Neurotoxicology 30, 1127-1132
25. Cleeter, M.W.J., Chan, K.-Y., Gluck, C., Mehta, A., Hughes, D.A., Duchen, M., Wood, N.W., Hardy, J., Cooper, J.H. and Schapira, A.H. (2013) Glucocerebrosidase inhibition causes mitochondial dysfunction and free radical damage. Neurochem. Int. 62, 1-27
26. Dermentzaki, G., Dimitriou, E., Xilouri, M., Michelakakis, H. and Stefanis, L. (2013) Loss of β-glucocerebrosidase activity does not affect α-synuclein levels or lysosomal function in neuronal cells. PLoS ONE 8, e60674
27. Sardi, S.P., Singh, P., Cheng, S.H., Shihabuddin, L.S. and Schlossmacher, M.G. (2012) Mutant GBA1 expression and synucleinopathy risk: first insights from cellular and mouse models. Neurodegener. Dis. 10, 195-202
28. Sardi, S.P., Clarke, J., Kinnecom, C., Tamsett, T.J., Li, L.Y., Stanek, L.M., Passini, M.A., Grabowski, G.A., Schlossmacher, M.G., Sidman, R.L. et al. (2011) CNS expression of glucocerebrosidase corrects α-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy. Proc. Natl. Acad. Sci. U.S.A. 108, 12101-12106
29. Sardi, S.P., Clarke, J., Viel, C., Chan, M., Tamsett, T.J., Treleaven, C.M., Bu, J., Sweet, L., Passini, M.A., Dodge, J.C. et al. (2013) Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies. Proc. Natl. Acad. Sci. U.S.A. 110, 3537-3542
30. Schapira, A.H.V. and Gegg, M.E. (2013) Glucocerebrosidase in the pathogenesis and treatment of Parkinson disease. Proc. Natl. Acad. Sci. U.S.A. 110, 3214-3215
31. Bendikov-Bar, I., Maor, G., Filocamo, M. and Horowitz, M. (2013) Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase. Blood Cells Mol. Dis. 50, 141-145
32. Sun, Y., Liou, B., Xu, Y.H., Quinn, B., Zhang, W.J., Hamler, R., Setchell, K.D.R. and Grabowski, G.A. (2012) Ex vivo and in vivo effects of isofagomine on acid β-glucosidase variants and substrate levels in Gaucher disease. J. Biol. Chem. 287, 4275-4287
33. Patnaik, S., Zheng, W., Choi, J.H., Motabar, O., Southall, N., Westbroek, W., Lea, W.A., Velayati, A., Goldin, E., Sidransky, E. et al. (2012) Discovery, structure-activity relationship, and biological evaluation of noninhibitory small molecule chaperones of glucocerebrosidase. J. Med. Chem. 55, 5734-5748
34. Yang, C.Z., Rahimpour, S., Lu, J., Pacak, K., Ikejiri, B., Brady, R.O. and Zhuang, Z.P. (2013) Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones. Proc. Natl. Acad. Sci. U.S.A. 110, 966-971
35. Brady, R.O., Yang, C.Z. and Zhuang, Z.P. (2013) An innovative approach to the treatment of Gaucher disease and possibly other metabolic disorders of the brain. J. Inherit. Metab. Dis. 36, 451-454
36. Yap, T.L., Gruschus, J.M., Velayati, A., Westbroek, W., Goldin, E., Moaven, N., Sidransky, E. and Lee, J.C. (2011) α-Synuclein interacts with glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases. J. Biol. Chem. 286, 28080-28088
37. Yap, T.L., Velayati, A., Sidransky, E. and Lee, J.C. (2013) Membrane-bound α-synuclein interacts with glucocerebrosidase and inhibits enzyme activity. Mol. Genet. Metab. 108, 56-64
38. Cookson, M.R. (2011) A feedforward loop links Gaucher and Parkinson's diseases? Cell 146, 9-11
39. Reczek, D., Schwake, M., Schroder, J., Hughes, H., Blanz, J., Jin, X.Y., Brondyk, W., Van Patten, S., Edmunds, T. and Saftig, P. (2007) LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of β-glucocerebrosidase. Cell 131, 770-783
40. Velayati, A., DePaolo, J., Gupta, N., Choi, J.H., Moaven, N., Westbroek, W., Goker-Alpan, O., Goldin, E., Stubblefield, B.K., Kolodny, E. et al. (2011) A mutation in SCARB2 is a modifier in Gaucher disease. Hum. Mutat. 32, 1232-1238
41. Tamargo, R.J., Velayati, A., Goldin, E. and Sidransky, E. (2012) The role of saposin C in Gaucher disease. Mol. Genet. Metab. 106, 257-263
42. Ellen, S., Gupta, N., Velayati, A., Choi, J., Stubblefield, B., Sidransky, E. and Tayebi, N. (2010) Are mutations in LIMP-2 associated with myoclonic epilepsy in patients with Gaucher disease? Mol. Genet. Metab. 99, S17
43. Sevlever, D., Jiang, P.Z. and Yen, S.H.C. (2008) Cathepsin D is the main lysosomal enzyme involved in the degradation of α-synuclein and generation of its carboxy-terminally truncated species. Biochemistry 47, 9678-9687